<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469504</url>
  </required_header>
  <id_info>
    <org_study_id>2017_06</org_study_id>
    <secondary_id>2019-A00632-55</secondary_id>
    <nct_id>NCT04469504</nct_id>
  </id_info>
  <brief_title>Preoperative Prehabilitation for Sarcopenic Patients Prior to Pancreatic Surgery for Cancer</brief_title>
  <acronym>PSOAS</acronym>
  <official_title>Prehabilitaion Program for Sarcopenic Patients Prior to Pancreaticoduodenectomy for Periampullary Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupement Interrégional de Recherche Clinique et d'Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Santélys</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major digestive surgery is associated with a significant rate of postoperative complications.
      To improve postoperative outcome, efforts are focused on postoperative course leading to the
      concept of rehabilitation. However, the rehabilitation concept does not allow to improve
      muscular and functional reserves at the time of surgery. Sarcopenia is a condition
      characterized by loss of skeletal muscle mass and function. Also, the prevalence of
      sarcopenia in patients with cancer is high and has a prevalence of around 25% in patients
      with pancreatic cancer, with a considerable impact on postoperative and survival outcomes.

      The hypothesis is the preoperative management of sarcopenia by a rehabilitation program could
      improve patients' operative outcomes by reducing the rate of postoperative complications.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative severe pancreatic fistula (Grade B and C)</measure>
    <time_frame>at 90 days</time_frame>
    <description>Pancreatic fistula as defined by the International Study Group of pancreatic Fistula (ISGPF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Severe postoperative complications</measure>
    <time_frame>at 90 days</time_frame>
    <description>Grade &gt; IIIa (Clavien-Dindo classification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 1 year and at 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Program acceptance measure by Modified ACCEPT© questionnaire</measure>
    <time_frame>at 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of program completion</measure>
    <time_frame>at 30 days</time_frame>
    <description>self questionnaire to measure opinion with respect of rehabilitation program</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction questionnaire by EVAN-G</measure>
    <time_frame>at 30 days</time_frame>
    <description>EVAN-G general patient satisfaction questionnaire consisting of 26 items divided into 6 sub-sections scoring on a scale from 0 to 100. It is designed to report perioperative problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction questionnaire by the questionnaire for satisfaction of hospitalized (QSH-45)</measure>
    <time_frame>at 30 days</time_frame>
    <description>French self-administered instrument for measuring hospitalized patients' satisfaction based on the patient's point of view. QSH contained 45 items describing 9 dimensions, leading to 2 composite scores (staff and structure index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by EORTC-QLQc30 scale</measure>
    <time_frame>at 1 month, 3 months, 6 months and at 1 year</time_frame>
    <description>The QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. The questionnaire includes one global health status/QoL scale, five functional scales and three symptom scale. Each scale is scored from 0 to 100. A high score on a scale indicate a good outcome for the dimension of QoL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>PREHAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prehabilitation program</intervention_name>
    <description>4-week trimodal prehabilitation program: Exercise, nutritional supplementation, and psychological support</description>
    <arm_group_label>PREHAB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral Impact</intervention_name>
    <description>perioperative immunonutrition by ORAL IMPACT</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing pancreaticoduodenectomy for cancer

          -  Sarcopenic status

        Exclusion Criteria:

          -  Age younger than 18 years

          -  Medical contraindications including cardiovascular disease or clinically significant
             vascular disease

          -  Physical inability to exercise

          -  Emergent surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehdi ELAMRANI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mehdi ELAMRANI, MD</last_name>
    <phone>0320444465</phone>
    <phone_ext>+33</phone_ext>
    <email>mehdi.elamrani@chru-lille.fr</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>morbimortality</keyword>
  <keyword>Prehabilitaion</keyword>
  <keyword>pancreatic surgery</keyword>
  <keyword>cephalic duodenopancreatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

